The paper published in Nature Communications by scientists at Ajou University and Orum Therapeutics was covered by multiple media outlets. The paper describes the preclinical characterization of a novel monoclonal antibody, called RT11-i, designed to be internalized by the cell and to directly target the activated form of RAS. This data shows that  Orum's cell penetrating antibody technology has the ability to selectively inhibit activated RAS to achieve anti-tumor activity with a systemically administered monoclonal antibody.

FierceBiotech notes, "Successfully blocking RAS activity could be important for often deadly pancreatic cancers, 95% of which have RAS mutations, as well as for colorectal cancer (45%), lung cancer (35%) and melanoma, the deadliest of the skin cancers."

Read more here: